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Alzheimer’s disease (AD) in patients receiving stable donepezil
treatment compared with not providing memantine.
METHODS: Data from a U.S. multicenter randomised clinical
trial that compared memantine versus placebo in moderate to
severe AD patients on stable doses of donepezil was used to eval-
uate the cost effectiveness of providing memantine to donepezil.
Using methodology developed by Kurz et al., patients were clas-
siﬁed at each visit as dependent or non-dependent according to
their ADCS-ADL19 scores. Mean weekly costs were estimated
from the National Health Service and Personal Social Services
perspectives for patients with MMSE £14 that participated in a
UK epidemiological study—the LASER-AD study. QALYs per
dependency were estimated from a Danish Study. Per week mean
acquisition cost and effectiveness of treatment were £975;
0.6511 and £288; 0.3207 for dependent and non-dependent
patients. Total drug costs for the 24-week period were £492 for
donepezil and £937 for memantine plus donepezil. Costs,
QALYs and time of non-dependence were associated with each
dependency level and added to obtain total outcomes over the
24-week study period. RESULTS: Over the evaluation period,
memantine added to patients stabilised on donepezil was 
associated with an additional 0.0112 QALYs, an additional 
1.77 weeks of independence and a £771 cost reduction compared
with donepezil alone. The cost reduction is not statistically sig-
niﬁcant but suggests that clinical advantages offset some of the
cost of adding memantine. CONCLUSION: This analysis sug-
gests that memantine treatment provided to patients receiving
stable donepezil treatment is cost-effective compared with not
adding memantine. As costs and QALYs were assessed retro-
spectively, further prospective studies are required to support this
ﬁnding.
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OBJECTIVE: To determine persistence of treatment with
donepezil (DON), rivastigmine (RIV), galantamine (GAL) and
memantine (MEM) in patients with Alzheimer Dementia (AD)
in a Spanish population setting. METHODS: Retrospective AD
cohort study performed in nine Primary Care Health Centers
from four different Autonomous Communities (Andalucia,
Cantabria, Cataluña & Valencia) in Spain. Descriptive standard
analyses were performed. ANOVA and Chi-square tests were
used to show the differences among mean duration therapy and
treatment adherence after 52 weeks. A Kaplan-Meier survival
analysis was applied to assess overall pattern persistence after
three-year of follow up, and the log rank test was used for testing
signiﬁcance. RESULTS: A total of 299 patients (44.8% female),
mean age 77.88 years (SD: 6.32), were included; 101 DON
(34%), 105 RIV (35%), 51 GAL (17%) and 42 MEM (14%).
Mean treatment duration was slightly longer and signiﬁcant for
DON patients 83.3 weeks (95% CI: 72.7–93.9) than for the
other drugs: RIV; 76.6 (66.0–87.3), GAL; 65.8 (55.3–76.3),
MEM; 60.9 (48.8–73.1), p = 0.049. Treatment adherence after
52 weeks was numerically higher with DON (63%) than with
the other medications: RIV; 55%, GAL; 55%, and MEM; 52%,
p = 0.525. Overall persistence of treatment was signiﬁcantly
higher with DON [median time; 70.3 weeks (95% CI:
49.8–90.7)] than for the others drugs: RIV [56.1 weeks
(36.1–76.2)], GAL [56.7 weeks (41.1–72.3)] and MEM [52.1
weeks (35.2–69.1)], Log Rank = 10.16, p = 0.017. CONCLU-
SION: This retrospective study including Spanish AD patients
showed numerically differences on treatment adherence after one
year of therapy among the four antidementia medications com-
mercially available. The global treatment persistence during the
three-year follow up was signiﬁcantly higher in patients treated
with donepezil compared to those who received rivastigmine,
galantamine or memantine.
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OBJECTIVE: To estimate the overall burden of pediatric
epilepsy on the family and Irish health care system and to estab-
lish whether there is a relationship between epilepsy proﬁle and
this burden. METHOD: The sample was drawn from a popula-
tion of children with epilepsy attending a tertiary pediatric neu-
rology clinic in Dublin. Data was collected prospectively on
health care resource use and time lost from school and work.
Diary cards were completed at three monthly intervals.
RESULTS: Complete data was available on 127 children aged
15 months to 16.7 years (median 8.8), 54% were male and 52%
lived in a rural setting. A total of 61% had cryptogenic or symp-
tomatic epilepsy, 63% had partial seizures and 53% had frequent
seizures (>10 seizures/month). The annual cost of epilepsy was
signiﬁcantly higher for those with cryptogenic/symptomatic
epilepsy (€9248) and frequent seizures (€9145) relative to idio-
pathic epilepsy (€2600) and no/infrequent seizures (€3951) (P <
0.0001). Children with frequent seizures had a higher risk of
being hospitalised (P = 0.03) and lost more days at school (P <
0.0005). 50% of families contacted the pediatric liaison nurse,
and 12% made more than 5 contacts. Five percent of children
attended their GP while 37% of families had independently
sought complementary medicine. CONCLUSIONS: The eco-
nomic and social burden of pediatric epilepsy is substantial and
relates to the epilepsy syndrome and frequency of seizures. In
this prospective study a large dependence on epilepsy liaison
nurse support was found, an area that requires extra resources.
A large number of families also sought advice from non medical
sources.
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OBJECTIVES: The aim of this prospective study was to deter-
mine the relationship between seizure type, seizure frequency and
epilepsy syndrome on the quality of life of both the child and
family over a one year period. METHOD: The sample was
drawn from a population of children with epilepsy attending a
tertiary Paediatric Neurology service in Dublin. Data was col-
lected on seizure type and frequency, epilepsy syndrome, physi-
A130 Abstracts
cal and cognitive ability, behaviour, co-morbidities, demographic
and socio-economic variables. The attending parent completed
the Child Health Questionnaire 50-item version (CHQ-50) for
children ≥5 years at baseline and 12 months. The Impact of 
Paediatric Epilepsy Scale (IPES) was used to measure burden on
families. RESULTS: 132 children were enrolled and data was
available on 127. The median age was 8.8 years and 54% were
male. 63% had partial seizures and 61% of all children had cryp-
togenic or symptomatic epilepsy. 53% of children had frequent
seizures (>10/month). 93 children ≥5 years were included in the
QOL analysis. Children with frequent seizures scored signiﬁ-
cantly worse than those with no/infrequent seizures on 10/14 and
11/14 of the CHQ-50 subscales tested and both IPES scores at
baseline and 12 months respectively. Children with crypto-
genic/symptomatic epilepsy scored signiﬁcantly worse than those
with idiopathic epilepsy. No such differences were found
between seizure types and there were no differences between
ﬁndings at baseline and 12 months. CONCLUSIONS: The
burden of epilepsy on children and their families is substantial.
Seizure frequency and epilepsy syndrome rather than seizure type
determines the impact.
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OBJECTIVE: To describe the incidence, prevalence and man-
agement of migraine in the UK. METHODS: The study consid-
ered patients >18 years with a record of migraine (diagnosed
migraine) or headache with a prescription for a triptan, ergot
alkaloid, prophylactic or a combined anti-emetic and analgesic
treatment (undiagnosed migraine), registered between
1994–2003 on the General Practice Research Database (GPRD)
covering 4.6% of the UK population. Incidence and prevalence
were estimated from the GPRD population, prescribing and
management trends were examined. RESULTS: A total of
108,652 migraine patients, average age 45 years, were identiﬁed;
76% were female. The incidence of migraine was 11/1000
person-years for females and 3/1000 person-years for males. The
female: male ratio was on average 3 :1. Prevalence over the 10-
year period was 6.9%, at the low end of rates reported in the
literature. Annual prevalence increased over time from 2.4% in
1995 to 4.5% in 2003. Among females peak prevalence is seen
in the 31–59 age group, for males this is 18–29. The percentage
of patients with undiagnosed migraine was stable at around 12%
over the period. The average annual number of migraine-related
GP consultations is 3 (95% CI 2–6). In diagnosed migraine, trip-
tans, anti-emetics and prophylactics are prescribed almost
equally at 34%, 31% and 33% respectively. In undiagnosed
migraine prophylactics (48%) are most prescribed. Younger
patients (<30) receive less triptans (19%) but more anti-emetics
(49%) than other age-groups. Ergots are rarely prescribed.
Triptan prescriptions increased from 19% in 1994 to 42% in
2003, excluding analgesics. CONCLUSION: Not all patients
will consult a GP for migraine explaining the low prevalence and
incidence rates. A substantial number of migraine patients are
not diagnosed. A peak prevalence in the productive age, high
annual consultation rates and high triptan prescription rates
suggest that migraine represents a sizeable economic burden to
the UK.
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OBJECTIVE: To carry out a one-year cost beneﬁt analysis from
the Year-2005 societal perspective of the acute migraine attacks
treatment in Spain. METHODS: A cost-beneﬁts analysis was
performed. Model data were obtained from the Spanish cohort
of a multinational survey assessing impact of migraine on dis-
ability, absenteeism and health care resource utilization. Beneﬁts
(days of disability and health resources use avoided) were com-
puted indirectly by imputation of the effectiveness (anti-migraine
complete response) obtained from a published efﬁcacy meta-
analysis of available triptans in Spain. Human capital method
was used for imputation indirect costs and beneﬁts. Results are
expressed as net beneﬁts. Sensibility analysis was performed.
RESULTS: The number of annual migraine attacks was 57.7
(95% conﬁdence interval: 44.5–77.2), the paid and unpaid
annual lost-workday-equivalents (LWDE) were 34.9 (22.8–68.3)
and 37.5 (27.0–54.1), respectively. The annual cost of untreated
migraine was €4077.70 (3145.1–5451.0). Migraine treatment
reduced the number of LWDEs per year between 7.5 (5.2–12.7)
with zolmitriptan-2.5, to 14.7 (10.1–24.8) with eletriptan-40
and rizatriptan-10. Compared with no-treatment, the average
annual net beneﬁts obtained were: eletriptan-40; €269.50
(207.9–360.3), rizatriptan-10; €226.20 (174.5–302.4), suma-
triptan-50; €185.80 (143.3–248.4); naratriptan-2.5; €126.40
(97.5–169.0), and almotriptan-12.5; €8.40 (6.4–11.2).
Zolmitriptan-2.5, zolmitriptan-5, and sumatriptan-100 showed
no net beneﬁts. Results were robust to the sensitivity analyses
throughout different scenarios (number of migraine attacks,
salary, cost of migraine attack), except when minimal ofﬁcial
salary was used in the model. CONCLUSIONS: Compared with
existing triptans, eletriptan-40 showed the higher monetary net
beneﬁt over the untreated migraine attack alternative, yielding
more savings to the Society.
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OBJECTIVE: To perform cost-effectiveness analysis of betahis-
tine vs. cinnarizine for vertigo in Russia. METHODS: A total of
240 patients with vertigo were randomized for betahistine 16mg
3 times a day (group B) or cinnarizine 25mg 3 times a day (group
C) for 3 months. 11 parameters of health status and functional
abilities (such as dizziness, nausea, ability to use public transport
and others) were measured before the study and by the end of
each month using 5-score scale. Absence of severe and moderate
functional disabilities (3 scores and more) for all 11 parameters
by the end of treatment was the criteria of effectiveness. Direct
medical costs were taken into account from the health care
system point of view. RESULTS: A total of 215 patients ﬁnished
the study. There was signiﬁcant positive dynamics in both groups
but in group B positive changes occurred earlier and were more
expressed. 86% (95% CI 79.5–92.5%) of patients in B group
and 39% (95% CI 29.6–48.4%) in group C had no severe and
moderate functional disabilities by the end of study. Median
direct cost was 9177.2 rubles ($328 USD) in group B and 6425.6
rubles ($229) in group C. Betahistine was signiﬁcantly more
effective and more costly. Incremental CER was 5854.47 extra
